These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1333 related articles for article (PubMed ID: 30356138)
21. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Ashworth A J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545 [TBL] [Abstract][Full Text] [Related]
22. DNA damage response as a therapeutic target in gynecological cancers. Leary A; Auguste A; Mesnage S Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135 [TBL] [Abstract][Full Text] [Related]
23. [Impairment of DNA damage response and cancer]. Rancoule C; Vallard A; Guy JB; Espenel S; Sauvaigo S; Rodriguez-Lafrasse C; Magné N Bull Cancer; 2017 Nov; 104(11):962-970. PubMed ID: 29132683 [TBL] [Abstract][Full Text] [Related]
24. The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors sole the problem? Sadoughi F; Mirsafaei L; Dana PM; Hallajzadeh J; Asemi Z; Mansournia MA; Montazer M; Hosseinpour M; Yousefi B DNA Repair (Amst); 2021 May; 101():103074. PubMed ID: 33640757 [TBL] [Abstract][Full Text] [Related]
25. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor. Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154 [TBL] [Abstract][Full Text] [Related]
26. Targeting DNA repair and replication stress in the treatment of ovarian cancer. Murai J Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177 [TBL] [Abstract][Full Text] [Related]
27. Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice. Helleday T Curr Opin Oncol; 2013 Nov; 25(6):609-14. PubMed ID: 24097104 [TBL] [Abstract][Full Text] [Related]
28. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Smith J; Tho LM; Xu N; Gillespie DA Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966 [TBL] [Abstract][Full Text] [Related]
29. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Haynes B; Murai J; Lee JM Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007 [TBL] [Abstract][Full Text] [Related]
30. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437 [TBL] [Abstract][Full Text] [Related]
31. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment. Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572 [TBL] [Abstract][Full Text] [Related]
32. New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response. Luo Y; Leverson JD Expert Rev Anticancer Ther; 2005 Apr; 5(2):333-42. PubMed ID: 15877529 [TBL] [Abstract][Full Text] [Related]
33. Targeting DNA repair mechanisms in cancer. Furgason JM; Bahassi el M Pharmacol Ther; 2013 Mar; 137(3):298-308. PubMed ID: 23107892 [TBL] [Abstract][Full Text] [Related]
34. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer. Gralewska P; Gajek A; Marczak A; Rogalska A J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968 [TBL] [Abstract][Full Text] [Related]
35. An update on small molecule compounds targeting synthetic lethality for cancer therapy. Luo J; Li Y; Zhang Y; Wu D; Ren Y; Liu J; Wang C; Zhang J Eur J Med Chem; 2024 Nov; 278():116804. PubMed ID: 39241482 [TBL] [Abstract][Full Text] [Related]
36. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link-generating agents in vitro and in vivo. Wang HC; Lee AY; Chou WC; Wu CC; Tseng CN; Liu KY; Lin WL; Chang FR; Chuang DW; Hunyadi A; Wu YC Mol Cancer Ther; 2012 Jul; 11(7):1443-53. PubMed ID: 22532598 [TBL] [Abstract][Full Text] [Related]
38. Strategies for targeting the DNA damage response for cancer therapeutics. Zhang D; Wang HB; Brinkman KL; Han SX; Xu B Chin J Cancer; 2012 Aug; 31(8):359-63. PubMed ID: 22704491 [TBL] [Abstract][Full Text] [Related]
39. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Ngoi NYL; Pham MM; Tan DSP; Yap TA Trends Cancer; 2021 Oct; 7(10):930-957. PubMed ID: 34215565 [TBL] [Abstract][Full Text] [Related]
40. Targeting the DNA damage response for cancer therapy. Curtin NJ Biochem Soc Trans; 2023 Feb; 51(1):207-221. PubMed ID: 36606678 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]